preventable drug-related admissions are nonsteroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin, beta-blockers, antiepileptics, diuretics, sulfonylureas, digoxin, inhaled corticosteroids, nitrates, and insulin (Howard et al., 2003). From a purely financial perspective, improving databases that monitor drug interactions is advantageous. Zynx Health representative Scott Weingarten asserted that a perfect drug information database could potentially save the U.S. health-care system $4.5 billion per year (Hillestad et al., 2005).


Although health-care systems have a structural framework in place for capturing and evaluating DDIs (see Figure 5-1), there are several problems with current information-capture systems. Multiple drug compendia exist, including Clinical Pharmacology Online, Drug Interaction Facts, and First Databank. However, these different systems often disagree on which

FIGURE 5-1 Adverse drug event surveillance: evaluation process in the Duke University Health System.

SOURCE: Peter Kilbridge, workshop presentation.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement